IL-23 Is essential for the development of Elastase-induced pulmonary inflammation and emphysema

American Journal of Respiratory Cell and Molecular Biology

Volumn 55, Issue 5, 2016, Pages 697-707

  Fujii, Utako ^a   Miyahara, Nobuaki ^a,b   Taniguchi, Akihiko ^a   Waseda, Koichi ^a   Morichika, Daisuke ^a   Kurimoto, Etsuko ^a   Koga, Hikari ^a   Kataoka, Mikio ^a,b   Gelfand, Erwin W ^c   Cua, Daniel J ^d   Yoshimura, Akihiko ^e   Tanimoto, Mitsune ^a   Kanehiro, Arihiko ^a  

^a KumamotoUniversity Graduate School of Medicine   (United States)

^b OKAYAMA UNIVERSITY   (Japan)

^c DEPARTMENT OF MEDICINE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e School of Medicine Graduate School of Medicine   (Japan)

Author keywords

Chronic obstructive pulmonary disease; IL 17; Th17

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; IL 23P40 MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23P19; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCLONAL ANTIBODY; PANCREATIC ELASTASE; UNCLASSIFIED DRUG; CHEMOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ELASTASE INDUCED PULMONARY INFLAMMATION; ELASTASE-INDUCED EMPHYSEMA; FEMALE; HISTOPATHOLOGY; LUNG COMPLIANCE; LUNG HOMOGENATE; LUNG LAVAGE; LUNG PARENCHYMA; MOUSE; NEUTROPHILIA; NONHUMAN; PNEUMONIA; TH17 CELL; WILD TYPE MOUSE; ANIMAL; BRONCHOALVEOLAR LAVAGE FLUID; C57BL MOUSE; CD4+ T LYMPHOCYTE; CHEMICALLY INDUCED; COMPLICATION; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; KINETICS; LUNG; LUNG EMPHYSEMA; LYMPHOCYTE COUNT; METABOLISM; PATHOLOGY; PIG;

ANIMALS; ANTIBODIES, MONOCLONAL; BRONCHOALVEOLAR LAVAGE FLUID; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES; DISEASE PROGRESSION; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-23; KINETICS; LUNG; LYMPHOCYTE COUNT; MICE, INBRED C57BL; PANCREATIC ELASTASE; PNEUMONIA; PULMONARY EMPHYSEMA; SUS SCROFA;

EID: 84994430030     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2016-0015OC     Document Type: Article

References (49)

1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-365.
2. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011;378:1015-1026.
3. Borchers MT, Wesselkamper SC, Curull V, Ramirez-Sarmiento A, S anchez-Font A, Garcia-Aymerich J, Coronell C, Lloreta J, Agusti AG, Gea J, et al. Sustained CTL activation by murine pulmonary epithelial cells promotes the development of COPD-like disease. J Clin Invest 2009;119:636-649.
4. Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5: 478-485.
5. Vargas-Rojas MI, Raḿirez-Venegas A, Limó n-Camacho L, Ochoa L, Herná ndez-Zenteno R, Sansores RH. Increase of Th17 cells in peripheral blood of patients with chronic obstructive pulmonary disease. Respir Med 2011;105:1648-1654.
6. Eustace A, Smyth LJC, Mitchell L, Williamson K, Plumb J, Singh D. Identification of cells expressing IL-17A and IL-17F in the lungs of patients with COPD. Chest 2011;139:1089-1100.
7. Di Stefano A, Caramori G, Gnemmi I, Contoli M, Vicari C, Capelli A, Magno F, DAnna SE, Zanini A, Brun P, et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol 2009;157:316-324.
8. Kurimoto E, Miyahara N, Kanehiro A, Waseda K, Taniguchi A, Ikeda G, Koga H, Nishimori H, Tanimoto Y, Kataoka M, et al. IL-17A is essential to the development of elastase-induced pulmonary inflammation and emphysema in mice. Respir Res 2013;14:5.
9. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-725.
10. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910-1914.
11. Chang Y, Nadigel J, Boulais N, Bourbeau J, Maltais F, Eidelman DH, Hamid Q. CD8 positive T cells express IL-17 in patients with chronic obstructive pulmonary disease. Respir Res 2011;12:43.
12. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006;116:1218-1222.
13. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-1674.
14. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu M-C, Wang Y, Li S, et al.; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-1684.
15. Hayes JA, Korthy A, Snider GL. The pathology of elastase-induced panacinar emphysema in hamsters. J Pathol 1975;117:1-14.
16. Kaplan PD, Kuhn C, Pierce JA. The induction of emphysema with elastase. I. The evolution of the lesion and the influence of serum. J Lab Clin Med 1973;82:349-356.
17. Fujii U, Miyahara N, Taniguchi A, Kawano K, Waseda K, Morichika D, Koga H, Kataoka M, Tanimoto M, Yoshimura A, et al. Importance of IL-23 to the development of elastase-induced pulmonary inflammation and emphysema [abstract]. Am J Respir Crit Care Med 2015;191:A2715.
18. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421:744-748.
19. Waseda K, Miyahara N, Taniguchi A, Kurimoto E, Ikeda G, Koga H, Fujii U, Yamamoto Y, Gelfand EW, Yamamoto H, et al. Emphysema requires the receptor for advanced glycation end-products triggering on structural cells. Am J Respir Cell Mol Biol 2015;52:482-491.
20. Inoue K, Takano H, Yanagisawa R, Sakurai M, Abe S, Yoshino S, Yamaki K, Yoshikawa T. Effects of components derived from diesel exhaust particles on lung physiology related to antigen. Immunopharmacol Immunotoxicol 2007;29:403-412.
21. Inoue K, Takano H, Yanagisawa R, Sakurai M, Abe S, Yoshino S, Yamaki K, Yoshikawa T. Effects of nanoparticles on lung physiology in the presence or absence of antigen. Int J Immunopathol Pharmacol 2007;20:737-744.
22. Inoue K, Takano H, Ichinose T, Tomura S, Yanagisawa R, Sakurai M, Sumi D, Cho AK, Hiyoshi K, Kumagai Y. Effects of naphthoquinone on airway responsiveness in the presence or absence of antigen in mice. Arch Toxicol 2007;81:575-581.
23. Fuchimoto Y, Kanehiro A, Miyahara N, Koga H, Ikeda G, Waseda K, Tanimoto Y, Ueha S, Kataoka M, Gelfand EW, et al. Requirement for chemokine receptor 5 in the development of allergen-induced airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol 2011;45:1248-1255.
24. Fujita M, Shannon JM, Irvin CG, Fagan KA, Cool C, Augustin A, Mason RJ. Overexpression of tumor necrosis factor-A produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001;280:L39-L49.
25. Ikeda G, Miyahara N, Koga H, Fuchimoto Y, Waseda K, Kurimoto E, Taniguchi A, Tanimoto Y, Kataoka M, Tanimoto M, et al. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema. Am J Respir Cell Mol Biol 2014;50:18-29.
26. Dunnill MS. Evaluation of a simple method of sampling the lung for quantitative histological analysis. Thorax 1964;19:443-448.
27. Waseda K, Miyahara N, Kanehiro A, Ikeda G, Koga H, Fuchimoto Y, Kurimoto E, Tanimoto Y, Kataoka M, Tanimoto M, et al. Blocking the leukotriene B4 receptor 1 inhibits late-phase airway responses in established disease. Am J Respir Cell Mol Biol 2011;45:851-857.
28. Miyahara N, Swanson BJ, Takeda K, Taube C, Miyahara S, Kodama T, Dakhama A, Ott VL, Gelfand EW. Effector CD81 T cells mediate inflammation and airway hyper-responsiveness. Nat Med 2004;10: 865-869.
29. Nishimori H, Maeda Y, Teshima T, Sugiyama H, Kobayashi K, Yamasuji Y, Kadohisa S, Uryu H, Takeuchi K, Tanaka T, et al. Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by downregulating Th1 and Th17. Blood 2012;119:285-295.
30. Ishii Y, Itoh K, Morishima Y, Kimura T, Kiwamoto T, Iizuka T, Hegab AE, Hosoya T, Nomura A, Sakamoto T, et al. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J Immunol 2005;175: 6968-6975.
31. Grumelli S, Corry DB, Song L-Z, Song L, Green L, Huh J, Hacken J, Espada R, Bag R, Lewis DE, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004;1:e8.
32. Hodge G, Nairn J, Holmes M, Reynolds PN, Hodge S. Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects. Clin Exp Immunol 2007;150:22-29.
33. Okamoto S, Fujiwara H, Nishimori H, Matsuoka K, Fujii N, Kondo E, Tanaka T, Yoshimura A, Tanimoto M, Maeda Y. Anti-IL-12/23 p40 antibody attenuates experimental chronic graft-versus-host disease via suppression of IFN-g/IL-17-producing cells. J Immunol 2015; 194:1357-1363.
34. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-240.
35. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ. Divergent pro-And antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-1957.
36. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008;223:87-113.
37. Roos AB, Sethi S, Nikota J, Wrona CT, Dorrington MG, Sandé n C, Bauer CM, Shen P, Bowdish D, Stevenson CS, et al. IL-17A and the promotion of neutrophilia in acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192:428-437.
38. Roos AB, Sandé n C, Mori M, Bjermer L, Stampfli MR, Erjefä lt JS. IL-17A is elevated in end-stage chronic obstructive pulmonary disease and contributes to cigarette smoke-induced lymphoid neogenesis. Am J Respir Crit Care Med 2015;191:1232-1241.
39. Zelante T, De Luca A, Bonifazi P, Montagnoli C, Bozza S, Moretti S, Belladonna ML, Vacca C, Conte C, Mosci P, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007;37:2695-2706.
40. Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan T, Blumenschein W, Churakovsa T, Low J, Presta L, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006;116: 1317-1326.
41. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, Cua DJ. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 2015;21:719-729.
42. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, doubleblind, placebo-controlled, crossover trial. Lancet 2009;373:633-640.
43. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P; Ustekinumab Crohns Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-Tosevere Crohns disease. Gastroenterology 2008;135:1130-1141.
44. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, et al.; CERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohns disease. N Engl J Med 2012;367:1519-1528.
45. Zhou H, Hua W, Jin Y, Zhang C, Che L, Xia L, Zhou J, Chen Z, Li W, Shen H. Tc17 cells are associated with cigarette smoke-induced lung inflammation and emphysema. Respirology 2015;20:426-433.
46. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger JG. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-130.
47. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rb1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699-5708.
48. Li J, Hsu HC, Mountz JD. The dynamic duo-inflammatory M1 macrophages and Th17 cells in rheumatic diseases. J Orthop Rheumatol 2013;1:4.
49. Arnold IC, Mathisen S, Schulthess J, Danne C, Hegazy AN, Powrie F. CD11c(1) monocyte/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL-23. Mucosal Immunol 2016;9:352-363.